MicroRNAs (miRs) {#S1}
================

MicroRNAs are a class of single-stranded, non-coding RNA molecules about 22 nucleotides in length that control gene expression at the post-transcriptional level ([@B1]). Initially discovered in 1993, they turned out to be important evolutionarily conserved endogenous molecules causing RNA silencing in a sequence-specific manner ([@B2]). The biogenesis of miRs is under tight temporal and spatial control and its dysregulation is associated with various diseases ([@B2]).

The Role of miRs in Myeloid Cells During Inflammation and Autoimmunity {#S2}
======================================================================

MicroRNAs are known to play a pivotal role in immunity, for example, by regulating toll-like receptor (TLR) signaling pathways ([@B3]). They can target multiple molecules, including TLRs themselves, their associated signaling proteins, transcription factors, and functional cytokines ([@B3]). While being crucial for physiological processes, several miRs exhibit altered expression under conditions of inflammation and autoimmune diseases.

Consistent with the fact that miR-146a controls innate immune cell and T cell responses, miR-146a was observed to be overexpressed in the peripheral blood mononuclear cells of patients with rheumatoid arthritis ([@B4]), Sjögren's syndrome ([@B5]), and myasthenia gravis ([@B6]). Furthermore, the miR-146a single-nucleotide polymorphism (SNP) rs2910164 was linked to the development of childhood-onset asthma in Mexican patients ([@B7]), rheumatoid arthritis ([@B8]), and psoriasis ([@B9]). In addition to these descriptive findings in humans, miR-146a was also shown to function as an anti-inflammatory regulator in different cell subsets in mice ([@B10]). In dendritic cells (DCs), silencing of miR-146a and miR-146b expression was observed to enhance the production of IL-12p70, IL-6, TNF-α, and IFN-γ ([@B11]). Conversely, miR-146a overexpression in DCs was found to reduce cytokine production ([@B11]).

Another important regulatory miR in the context of immunity and inflammation is miR-155. A study reported miR-155 exerting pro-inflammatory effects in clinical and experimental arthritis, based on the observation that miR-155 was upregulated in synovial membrane and synovial fluid macrophages from rheumatoid arthritis patients ([@B12]). Mechanistically, increased expression of miR-155 in CD14^+^ monocytes was connected to reduced expression of the miR-155 target Src homology 2-containing inositol phosphatase-1 (SHIP-1) ([@B12]). Expression of SHIP-1, which is known to act as an inhibitor of inflammation, was also observed to be decreased in CD68^+^ cells in the synovial lining layer of rheumatoid arthritis patients compared to osteoarthritis patients ([@B12]). SHIP downregulation by miR-155 in myeloid cells was found in other models of inflammation as well, e.g., after infection with *Francisella tularensis* novicida ([@B13]).

The Role of miRs in Myeloid Cells During Graft-Versus-Host Disease (GvHD) {#S3}
=========================================================================

In mouse models, GvHD biology was functionally linked to several miRs, e.g., miR-155 ([@B14], [@B15]), miR-100 ([@B16]), miR-146a ([@B17], [@B18]), miR-142 ([@B19]), miR-17-92 ([@B20]), miR-153-3p ([@B21]), and miR-29a ([@B22]).

Because miR-155 is known to regulate multiple steps in the activation of the innate immune system, a study addressed its role in DCs during GvHD in a murine model ([@B15]). By using miR-155^−/−^ bone marrow chimeric mice receiving allogeneic hematopoietic cell transplantation (allo-HCT) and miR-155^−/−^ recipient-type DCs, miR-155 deficiency in the latter cell subset was shown to cause protection from GvHD ([@B15]). Mechanistically, miR-155 deficiency led to dysregulation of the mitogen-activated protein kinase pathway and impaired DC migration toward adenosine triphosphate *in vitro* ([@B15]). In addition, activated miR-155^−/−^ DCs displayed reduced expression of different purinergic receptors and other inflammasome-associated genes ([@B15]). Functionally, caspase-1 cleavage and IL-1β production were found to be reduced in miR-155^−/−^ DCs upon activation. Consistent with the *in vitro* data, Nlrp3/miR-155 double knockout allo-HCT recipient mice displayed no increased protection from GvHD compared to Nlrp3^−/−^ recipients, indicating a functional connection between miR-155 and the Nlrp3 inflammasome ([@B15]).

While playing a crucial role in immune responses, miR-146a was also found to act as an important regulator of recipient-type DC activation during GvHD. In a murine model, miR-146a deficiency of the hematopoietic system or injection of recipient-type miR-146a^−/−^ DCs during allo-HCT was shown to cause GvHD exacerbation ([@B18]). Conversely, transfer of DCs transfected with miR-146a mimic was observed to reduce disease severity ([@B18]). Regarding the mechanism of action, absence of miR-146a in DCs increased activity of the JAK2/STAT1 pathway, leading to higher expression of class II transactivator (CIITA) and thereby causing elevated MHCII levels on the cell surface ([@B18]). Consistent with these findings, inhibition of JAK1/2 or CIITA knockdown in DCs was shown to prevent GvHD exacerbation induced by miR-146a^−/−^ DCs. At the same time, the G/C polymorphism rs2910164 within the miR-146a gene of human allo-HCT recipients, causing reduced miR-146a levels, was found to be connected to a higher risk of developing severe acute GvHD ([@B18]). The patients with said SNP in hematopoietic cells exhibited higher MHCII levels on monocytes, which could be targeted by JAK1/2 inhibition ([@B18]).

There is increasing evidence that serum or plasma miRs could be used as biomarkers and predict acute GvHD onset ([@B23]). A study suggested miR-153-3p as a potential biomarker for GvHD because miR-153-3p plasma levels were elevated on day seven after allo-HCT in the GvHD group compared to the control group even though GvHD had not occurred yet ([@B21]). Through bioinformatics analysis, indoleamine 2,3-dioxygenase (IDO) was found to be a potential target protein of miR-153-3p ([@B21]). The authors hypothesized that IDO might inhibit the development of acute GvHD through various cell types in addition to lymphocytes, such as DCs and myeloid-derived suppressor cells ([@B21]). In a previous study, IDO expression in donor precursors of plasmacytoid DCs had been shown to suppress GvHD activity of donor T cells and to influence their polarization in a murine model ([@B24]). A well-characterized subset of human myeloid-derived suppressor cells consisting of CD14^+^HLA-DR^low/neg^ cells was found to suppress T cell responses *via* IDO in patients with GvHD ([@B25]).

A recent study showed that miR-29a expression was significantly upregulated in the serum of patients at acute GvHD onset compared to patients without GvHD after allo-HCT ([@B22]). Serum miR-29a was also elevated as early as 2 weeks before time of diagnosis of acute GvHD compared to time-matched control subjects ([@B22]). In a murine model of acute GvHD, treatment with locked nucleic acid anti-miR-29a reduced mortality while retaining graft-versus-leukemia effect ([@B22]). Functionally, miR-29a was shown to activate DCs *via* TLR7 and TLR8 activation with consecutive NF-κB pathway activity and secretion of the pro-inflammatory cytokines TNF-α and IL-6 ([@B22]). Based on these different studies on miRs in GVHD this type of molecule could become a potential target for the modification of the allogeneic immune response using miR mimics and antagomirs.

Different miRs that were studied in the setting of GvHD are listed in Table [1](#T1){ref-type="table"}.

###### 

MicroRNAs (miRs) with a reported function in myeloid cells during graft-versus-host disease (GvHD).

  miR                              Functional role in myeloid cells during GvHD                                                       Reference
  -------------------------------- -------------------------------------------------------------------------------------------------- -----------
  miR-29a (pro-inflammatory)       miR-29a promotes inflammation through activation of DCs *via* TLR7 and TLR8                        ([@B22])
  miR-146a (anti-inflammatory)     miR-146a dampens the pro-inflammatory JAK/STAT/CIITA/MHCII axis in DCs                             ([@B18])
  miR-153--3p (pro-inflammatory)   miR-153-3p might enhance GvHD development by inhibiting IDO expression in different cell subsets   ([@B21])
  miR-155 (pro-inflammatory)       miR-155 is required for DC migration and Nlrp3 inflammasome activation in the GvHD context         ([@B15])
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